Based On The Clinical Benefits Demonstrated, Aduhelm® Is Only "Economic" In Alzheimers -- At $2,500 To $3,500 Per Year...

We have been over this ground literally hundreds of times here -- with other drug candidates, and FDA approvals (Vytorin^®, Celebrex^® and Asenepine^® leap immediately to mind -- as just three).

And so, I won't let my chin-waggle go on, and on -- at any great length then -- here. You may go read the reviews for yourself.

Certainly, everyone wants to see Alzheimers patients achieve a "gain, in function". However, the clinical results (in my experienced opinion) do not support a $55,000 to $65,000 per year price tag. The gains are modest, so too the price ought to be.

To be certain, Alzheimers is a very tough, often tragic very high burden disease. But the wealthy should not assume this is a panacea of any sort. My advice? If you are going the private pay route. . . here, do not expect miracles, even though the price looks a lot like the "miracle" pricing (in oncology) for pembrolizumab (Keytruda^®).

Onward -- so that's one "power alley" -- post, for the day. Grin.

नमस्ते